Article and Video CATEGORIES
Dr. Marco Ruiz is a Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, myelodysplastic syndrome, myelofibrosis, HIV related malignancies, stem cell transplants, geriatric oncology, and palliative medicine at the Miami Cancer Institute in Miami, Florida. He is also an experienced bone marrow transplant specialist and is active in cancer research. Growing up the son of a nurse, Dr. Ruiz knew at a young age that he wanted to pursue a career in medicine. But it was his father’s battle with cancer that sparked a passion for helping patients with the disease.
GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of fms related tyrosine kinase 3 (flt3) and myeloproliferative neoplasms (MPN) mutations in acute myeloid leukemia (AML) (¿Cuál es el rol de la tirosina cinasa 3 afín a FMS (FLT3) y de las mutaciones en las neoplasias mieloproliferativas (NMP) en la leucemia mieloide aguda (LMA)?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Acute Myeloid Leukemia & Myelodysplastic Syndrome, (Leucemia mieloide aguda y síndrome mielodisplásico).
We would like to thank the following company for their support of this program:
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi Caregiver and welcome to Grace. I'm sorry that you need to be here and hope we can help. Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...
Hi Bob, Welcome to Grace. I'm sorry about your sil. Unfortunately, cancer becomes resistant to TKIs like tagrisso. Sometimes all of the cancer becomes resistant at once and sometimes just parts...